Thiogenesis Therapeutics, Corp.
TTI.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.62% | -13.32% | 71.21% | 38.64% | 7.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.00% | 32.03% | 249.85% | 147.99% | 58.00% |
| Operating Income | 34.00% | -32.03% | -249.85% | -147.99% | -58.00% |
| Income Before Tax | 33.30% | -54.30% | -259.41% | -188.42% | -86.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 33.30% | -54.30% | -259.41% | -188.42% | -86.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.30% | -54.30% | -259.41% | -188.42% | -86.53% |
| EBIT | 34.00% | -32.03% | -249.85% | -147.99% | -58.00% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 41.12% | -35.80% | -226.42% | -181.90% | -81.36% |
| Normalized Basic EPS | 41.04% | -36.36% | -227.27% | -184.62% | -81.08% |
| EPS Diluted | 41.12% | -35.80% | -226.42% | -181.90% | -81.36% |
| Normalized Diluted EPS | 41.04% | -36.36% | -227.27% | -184.62% | -81.08% |
| Average Basic Shares Outstanding | 12.63% | 13.37% | 10.09% | 1.78% | 2.99% |
| Average Diluted Shares Outstanding | 12.63% | 13.37% | 10.09% | 1.78% | 2.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |